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Abstract
OPIOID DEPENDENCE AND ITS EFFECT ON ALCOHOL CONSUMPTION
Emily Vanessa Flores
Thesis Chair: Eric Stocks, Ph.D.
The University of Texas at Tyler
July 2020
Previous research has found dualistic effects on alcohol consumption with low doses of
buprenorphine increasing alcohol and higher doses of buprenorphine reducing alcohol
consumption in rats (Ciccocioppo et al., 2006). Other existing research on naloxone
treatment and alcohol consumption in opioid use has demonstrated that alcohol
consumption decreases after naloxone treatment in rats (Hyytia & Sinclair, 1993). Yet, no
research has been conducted on either rats or humans on the effects of buprenorphine and
naloxone medication combined. The effects of opioid maintenance therapy are
controversial and the relationship between alcohol consumption and opioid dependency
treatment are mainly based on literature review research and research conducted on rats.
Although literature reviews and research on rats provide insight and inferences on
possible outcomes in humans, further research on this topic is required and should be
conducted on patients in opioid dependency clinics to conclude if the results from
previous research on rats and literature reviews hold. The present study assessed alcohol
consumption among individuals diagnosed with opioid use disorder, it specifically
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assessed different opioid dependence treatment and their effect on alcohol consumption.
In this study, it was hypothesized patients who use buprenorphine/naloxone will consume
less alcohol than patients who use buprenorphine alone, even when controlling for pretreatment drinking rates. Results demonstrated participants in the buprenorphine group
reported binge drinking less frequently than participants in the buprenorphine/naloxone
group alone, although when adjusting for pre-treatment drinking, the effect does not hold
true.
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Introduction
In the last few years, the United States has experienced an opioid epidemic with
more people dying due to overdose than the number of people who died from HIV during
the height of that epidemic (Dowell et al., 2017). Overdoses are the leading cause of
injury death in the United States, accounting for one and a half times more deaths than
motor vehicle crashes (Rudd et al., 2016). Many individuals who misuse opioids started
with legitimate prescriptions of pain relievers and then became addicted following use
(Kolodny et al., 2015). This paper will discuss the effect opioid treatment has on alcohol
consumption by first discussing opioid use disorder, different treatment medications,
what we know about alcohol consumption and opioid dependency, and lastly the results
and implications of the study.

1

Literature Review
Opioid Use Disorder
Anyone can easily be exposed to opioids. Opioid use can begin at any age, but
problems associated with opioid use are more commonly observed in the late teenage years
or early 20s (American Psychiatric Association [APA], 2013). Rates of opioid use are
higher in males than in females (0.49% vs. 0.26%) with male to female ratio for opioids
other than heroin being 1.5:1 (APA, 2013). A study conducted by Han and colleagues
(2017) found that after weighing the 2015 National Survey on Drug Use and Health
(NSDUH) 91.8 million (37.8%) U.S civilian, noninstitutionalized adults used prescription
opioids. Out of those 11.5 million (4.7%) abused them and 1.9 million (.8%) had a use
disorder (Han et al., 2017).
Opioid medication is typically prescribed for individuals who are experiencing
pain, because the chemicals relax the body, although some opioids can be used to treat
other symptoms such as coughing and diarrhea, the majority of individuals are prescribed
for pain relieve purposes (National Institute on Drug Abuse [NIDA], 2019). Patients who
experience pain are not the only ones at risk of opioid use disorder, there are numerous
healthcare providers with opioid use disorder who will often write themselves prescriptions
or obtain them by diverting opioids that have been prescribed for patients (APA, 2013).
Common opioid prescriptions are hydrocodone, oxycodone, codeine, morphine,
oxymorphone, and fentanyl (Chen et al., 2016). When taken for non-medical reasons,
individuals can feel very relaxed and high which is why opioids can be very addictive.
Individuals who can no longer obtain prescribed opioids will usually try to obtain opioids
from several physicians before using heroin (APA, 2013) or often referred to as “doctor
shopping”. Heroin is one of the world’s most dangerous opioids (NIDA, 2019), and the
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cheapest, it is never prescribed, individuals usually buy from the illegal market. Rates for
heroin is higher in males than females with the ratio being 3:1 (APA, 2013). Possible
effects of opioid use can include dry mouth, drowsiness, confusion, nausea, constipation,
euphoria, slowed breathing (APA, 2013).
In the brain, opioids bind to and activate opioid receptors cells location in many
parts of the brain such as the spinal cord, and other organs in the body, specifically to the
parts of the body that involve feelings of pain and pleasure (NIDA, 2019). When they attach
to the receptors, they block the pain and there is a large release of dopamine throughout
the body (NIDA, 2019). The release of dopamine explains why individuals can become
highly addicted and want to continue use. The euphoric feelings of opioid use can easily
fade as tolerance develops, which leads to increased uncontrolled intake (Wang, 2019)
which then increases the chances of overdosing. Although studies do show prevalence
decreases with age, with the highest prevalence (0.82%) among adults age 29 years or
younger and decreasing to 0.09% among adults who are 65 years of age and older (APA,
2013).
Opioid use disorder is a mental disorder characterized as a problematic pattern of
opioid use leading to clinically significant impairment or distress in the past 12-month
period. Criteria for Opioid Use Disorder stated by the American Psychiatric Association
(2013) include a problematic pattern of opioid use leading to clinically significant
impairment or distress, as manifested by at least two symptoms listed in the Diagnostic
Statistical Manual Five (DSM-IV), occurring within a 12-month period.
Methadone
Methadone is the most widely used opioid agonist therapy in the world (Hser et al.,
2014). It was first developed in Germany, in the 1960s, during the Second World War with
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the purpose of treating pain (CAMH, 2012). Methadone blocks opioid receptors, which in
turns prevents withdrawal symptoms and reduces cravings (Radfar et al., 2019).
Methadone is made from chemicals in a lab, and a result it is considered a synthetic opioid
(CAMH, 2012). Studies show methadone is associated with higher retention in treatment
for opioid dependency than buprenorphine (Hser et al., 2014) due to individuals with opioid
use disorder being held more accountable in taking their prescribed dose of methadone
(Saloner et al., 2018). Methadone is a long-acting opioid agonist and very effective
(CAMH, 2012). However, its use requires careful observance of the dose being prescribed
and close monitoring because its long half-life increases the risk of overdose (Saloner et
al., 2018). Illicit opioid use is reduced more by higher doses of methadone than
buprenorphine (Kosten et al., 1993). Methadone if found to be more likely involved in
overdose deaths than any other prescribed drug (Terpening & Johnson, 2007). Doses of
methadone are in the range of 30 to 120 mg daily and individuals who take it must report
to the clinic for an observed daily dose at the beginning of treatment (Wang, 2019). Studies
have also found individuals with long term use of methadone perform poor than control
groups on all neuropsychological functioning (Darke et al., 2000). Indicating there is
cognitive decline due to use of methadone.
The effectiveness of opioid agonist medications such as buprenorphine and
methadone as a long-term maintenance therapy is the reason why a lot of individuals with
opioid use disorder seek out medicated treatment (Saloner & Barry, 2018). These
medications help eliminate physiological symptoms of opioid use disorder, helps with
cravings and withdrawal symptoms. Due to its great assistant and success in recovery, it is
important to look into the effects of the medication when other substances are being used
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in combination to the medication. For the purpose of this study, I focused on buprenorphine
maintenance treatment at a clinic whom does not prescribe methadone.
Buprenorphine
From the late 1990s to the present, the opioid crisis in the United States has raised
awareness of substance use disorders and has increased the number of medications used to
treat opioid dependency (Wang, 2019). A relatively newer treatment option is
buprenorphine which may increase safety among opioid-dependent patients (Kahan,
Srivastava, Ordean, & Cirone, 2011). Buprenorphine is starting to become the go-to
maintenance treatment due to it being safe enough to be prescribed a month’s supply versus
methadone which can be dangerous and must be given to every day (Saloner & Barry,
2018). Buprenorphine is a partial opioid agonist that relieves cravings and withdrawal
symptoms for 24 hours or longer. Unlike methadone patients cannot overdose on it nor can
they get high. Due to these reasons’ buprenorphine is preferred for patients at high risk of
methadone misuse, those with limited access to methadone treatment, and those who might
need shorter maintenance treatment. It is recommended that patients start taking
buprenorphine after they are in withdrawal or forty-eight hours after their last use of
opioids. Buprenorphine can also be given in a formulation with naloxone that provides
some protection against possible overdose if patient attempt to use again after starting
treatment (Volkow, 2018). This is important because individuals who might use after
starting treatment will not reach the same level of high due to the buprenorphine in their
system which can result in individuals using more than before which then increases the
chances of an overdose occurring.
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Just like methadone, buprenorphine targets mu opioid receptors (MORs) in the
brain to treat opioid dependence by reducing the withdrawal symptoms and well as the
cravings (Wang, 2019). Mu are opioid receptor subtypes with common analgesic effects
and has a unique effect and distribution in the brain. MORs in distinct brain regions, like
the basolateral amygdala and nucleus accumbent, trigger the euphoria and incentive
properties of rewarding stimuli. Since MOR triggers the reward center in the brain which
plays an important role in goal-directed behavior this aids individuals in creating new
habits that will prevent them from using again if winged off their medication (Wassum,
2009). When addictive behaviors develop then poor decision making and cognition
impairments shift from the goal directed behaviors to habitual behaviors causing
compulsive drug use. Medications for opioid dependency can be classified in three
groups: full agonists, partial agonists, and antagonists (Breneau et al., 2018). While
methadone is a full mu opioid agonist, buprenorphine is a partial mu opioid agonist, and
naloxone is an antagonist (Wang, 2019). Therefore, buprenorphine does not stimulate
MORs to the same degree as methadone does which makes it less likely to have
respiratory depression and euphoria. Doses of buprenorphine start between 2 to 8 mg
sublingually daily and individuals who take it are required to have a monthly visit at their
clinic.
Naloxone
Naloxone is an antagonist treatment that has achieved the least penetration of all
medications for opioid use disorder (Wang, 2019). Naloxone can be prescribed and
administered by any prover in the USA and does not poses any risk of diversion or
overdose. The effects of naloxone are due to the blockade of opiate receptors, there are an
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increasing number of reports which indicate that naloxone may have pharmacological
actions unrelated to opiate receptor blockade (Sawynok, Pinsky, & LaBella, 1979).
However, there is limited research related to naloxone and some research suggest
naloxone can provide the same result that buprenorphine can (Tanum et al., 2017). As
mentioned before buprenorphine targets the mu opioid receptors (MORs) and naloxone
targets mu, kappa, and delta opioid receptors to treat opioid overdose (Wang, 2019). It
can also be combined with buprenorphine to decrease the chance of overdose. In fact,
buprenorphine–naloxone treatment with patients who are dependent on heroin and
prescription opioids is more efficacious than placebo and as efficacious as moderate
doses of methadone (Fiellin et al., 2006).
Naloxone is often mistakenly thought to be the same thing as naltrexone because
they are both antagonists (Wang, 2019). Naloxone is a non-selective and competitive
opioid receptor agonist, and it is use for acute opioid overdose, and reversing mental
depression caused by opioids (Goodrich, 1990). Naltrexone is used primarily to treat
alcoholism or alcohol dependence (Wang, 2019). Buprenorphine-naloxone, also known
as Suboxone, can be giving in doses of 2mg/0.5mg, 1mg/4mg, 8mg/2mg, and 12mg/3mg
(Volkow, 2018).
Relationship between Opioid Treatment and Alcohol Consumption
Alcohol consumption is defined the amount of alcohol consumed on any single
day and is not intended as an average over several days (CDC, 2018). Approximately
one-third of individuals who receive opioid agonist treatment (OAT), such as
buprenorphine or buprenorphine/naloxone for the management of opioid dependency also
misuse alcohol (Soyka, 2015). Although it is known alcohol use is a risk factor for fatal
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overdose among individuals prescribed opioids (Degenhardt & Hall, 2013), little
guidance currently exists outlining effective management strategies for this patient
population (Nolan et al., 2016).
It is difficult to estimate prevalence of alcohol misuse among opioid dependent
individuals receiving opioid maintenance treatment is challenging. Previous research
varies in the literature among patient populations and treatment settings being studied due
to lack of standardization pertaining to alcohol use terminology and measurement of it.
There is more research conducted on alcohol consumptions and methadone but there is
less on buprenorphine or buprenorphine-naloxone.
A 12-month longitudinal study of individuals with both heroin addiction and
alcohol dependence demonstrated both methadone and buprenorphine to be association
with reduction in alcohol use, buprenorphine was more efficacious (Nava et al., 2008).
Previous research on rats found buprenorphine has dualistic effects on ethanol drinking;
low doses increase alcohol intake via stimulation of classic opioid receptors, whereas
higher doses reduce alcohol consumption via activation of NOP receptors (Ciccocioppo
et al., 2006). Alcohol preferring rats trained to drink 10% alcohol 2 hours/day were
injected with buprenorphine (.03, .3, 3.0, or 6.0 mg/kg intraperitoneally) 90 min before
access to ethanol (Ciccocioppo et al., 2006). Other research on naloxone has found that
naloxone treatment alone decreases alcohol consumption (Saloner & Barry, 2018).
Naltrexone, an antagonist like naloxone, appears to be an effective and safe strategy in
alcoholism treatment. Even though the sizes of treatment effects might appear moderate
in their magnitudes, these should be valued against the background of the relapsing
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nature of alcoholism and the limited therapeutic options currently available for its
treatment (Roesner et al., 2010).
Rational for Present Study
The effect opioid maintenance therapy on alcohol consumption is controversial and
no clear pattern has emerged (Soyka, 2015). Most research has been conducted on rats or
based of literature reviews. Buprenorphine has been found to carry a little risk of liver
toxicity and research data indicated that brief intervention strategies may help reduce
alcohol intake, but the existing evidence is still limited. The purpose of the study is to gain
a better understanding of opioid dependency and its relationship with alcohol in terms of
exploring the effect that opioid dependency medications has on the amount of alcohol
patients. Due to the opioid epidemic, it is important for scientists to gain a better
understanding of opioid use in order to better prevent, provide treatment, and gain
understanding of its effects.
Hypothesis
Patients who use buprenorphine/naloxone will consume less alcohol than patients
who use buprenorphine alone, even when controlling for pre-treatment drinking rates.
Methods
Participants
This study included 62 participants recruited from Foundation Medical Group an
opioid dependency clinic in Dallas, Texas. Two of those 62 participants were eliminated
from the study due to reporting they did not consume alcohol before starting treatment.
Group categorization was determined by buprenorphine and buprenorphine/naloxone
medication groups. The age range of participants was between 22 years of age up to 65
years of age. The study consisted of 38.3% female and 58.3% male. In addition, the
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population was 78.3% White, 19% Hispanic, 6.7% African American, 3.3% American
Indian, and 1.7% Native Hawaiian. There was no incentive given the participants for their
participation.
A statistical power analysis was performed for sample size estimation, based on
data from Ciccocioppo and his colleagues (2007), investigating buprenorphine dose and
reduction of alcohol intake. The effect size (ES) in this study was considered to be small
using Cohen's (1988) criteria. With an alpha = .05 and power = 0.80, the projected
sample size needed with this effect size (GPower 3.1 or other software) was
approximately N = 111 for this simplest between group comparison. Although I
attempted to collect data from this number of participants, the clinic in which data
collection took place shut down due to COVID-19. As such, the final sample size is
approximately half of the proposed target number.
Materials
This experiment consisted of a 6-page paper survey (refer to Appendix A). The
survey contained questions asking about their use of drugs (e.g. Alcohol, Opioids) and
other background information. In addition, the survey included a Beck’s Depression
Inventory (Beck et. al.,1988), Beck’s Anxiety Inventory (Bardhoshi et al.,2016), and
Multidimensional Scale of Perceived Social Support (Zimet et al., 1988). These measures
were scored by using their standard scoring protocol. Specifically, scores on the Beck’s
Depression Inventory were calculated by adding their total score and then categorized by
severity group. Scores on this measure can range from 0 to 63, with 20 indicating
moderate depression. Scores on the Beck’s Anxiety Inventory were calculated by their
total score and then categorized by severity group. Specifically, scores on the Beck’s
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Anxiety Inventory were calculated by adding their total score and then categorized by
severity group. Scores on this measure can range from 0 to 63, with 17 indicating
moderate anxiety. In addition, scores on the Multidimensional Scale of Perceived Social
Support were calculated by adding their total score and then calculating the mean. The
scores were then categorized by level of support. Scores on this measure can range from
1 to 7, with 3 indicating moderate support.
In order to test my hypothesis, current alcohol consumption was assessed using
two questions. The first addressed typical daily drinking habits (viz., “currently, how
many standard drinks containing alcohol do you have on a typical day?”) on a 0 (None)
to 6 (10 or more) point Ordinal scale. The second question addressed typical binge
drinking habits (viz., currently, how often do you have six or more drinks on one
occasion?) on a 0 (None) to 5 (Daily or Almost Daily) Ordinal scale. Participants also
answered a question about pre-treatment daily drinking habits (viz., before starting
treatment, ow many standard drinks containing alcohol do you have on a typical day?”)
on a 0 (None) to 6 (10 or more) point Ordinal scale for use as a covariate. Lastly, a
question was asked over which medication they were currently (buprenorphine or
buprenorphine/naloxone). Each participant was given the survey after being checked in
by the staff and were sent to the waiting room to be called in to see the doctor.
Procedure
Participants in the study were approached after being checked in the clinic. The
check-in process consistent of paying for treatment, leaving a urine sample, and getting
their blood pressure taken. After participants are checked-in they were required to sit in
the second waiting from in where they were informed about the study and asked if they
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would like to participate. The participants all received the same survey. They were asked
to answer truthfully and informed that their responses would not be shared with their
doctor. Lastly, they were debriefed upon turning in the survey.
Results
Participant Characteristics
To assess potential between-group differences in the sample, Beck’s Depression
Inventory, Beck’s Anxiety Inventory, and Multidimensional Scale of Perceived Social
Support were all subjected to independent-samples t-tests. All statistics are reported twotailed. On the Beck’s Depression Inventory, there were no differences between
participants in the buprenorphine group (M = 9.26, SD = 7.54) and
buprenorphine/Naloxone group (M = 12.17. SD = 8.07), t (46) = 1.25, p = .56. On the
Beck’s Anxiety Inventory, there were no differences between participants in the
buprenorphine group (M = 8.00, SD = 10.88) and buprenorphine/naloxone group (M =
8.19. SD = 8.67), t (41) = .06, p = 52. On the Multidimensional Scale of Perceived Social
Support, there were no differences between participants in the buprenorphine group (M =
5.24, SD = 1.73) and buprenorphine/naloxone group (M = 5.12 SD = 1.57), t (45) = .23, p
= .87.
Primary Hypothesis Test
To assess my hypothesis, I subjected the two drinking habit questions (daily
drinking and binge drinking) to independent-samples t-tests. I predict that participants
who used buprenorphine/naloxone will report less drinking than participants who use
buprenorphine alone. The results do not support this hypothesis. Participants self-reported
drinking frequency was no different in the buprenorphine group (M = 1.20, SD = .50)
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than in the buprenorphine/naloxone group. (M = 1.17, SD = .71)., t (58) = .17, p = .87,
Cohen’s d = .63. However, participants in the buprenorphine group reported binge
drinking less frequently (M = 1.16, SD = .63) than participants in the
buprenorphine/naloxone group (M = 1.43, SD = .95), t (58) = 1.24, p = .03, Cohen’s d =
.83.
To assess the degree to which these outcomes are affected by drinking habits prior
to treatment, I conducted set of ANCOVAS using frequency of daily drinking prior to
treatment as a covariate. The results suggest that, when controlling for pre-treatment
drinking habits, the frequency of daily drinking was no different in the buprenorphine
group (M = 1.92, SE = .13) than in the buprenorphine/naloxone group (M = 1.18, SE = .11),
F (1,57) = 1.29, p = .89, ηp2 = .00. Similarly, when controlling for pre-treatment drinking
habits, the frequency of binge drinking was lower in the buprenorphine group (M = 1.15,
SE = .17) than in the buprenorphine/naloxone group (M = 1.43, SE = .14), F (1,57) = 1.50,
p = .23, ηp2 = .03 although not significant.
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Discussion
Although previous research suggest that specific doses of the medications has an
effect on alcohol consumption in rats (Ciccocioppo et al., 2006), for the purpose of this
study the difference between medications and the effects it has on alcohol consumption
was examined before taking the doses into consideration. Other existing research on
naloxone treatment and alcohol consumption in opioid use has demonstrated that alcohol
consumption decreases after naloxone treatment in rats (Hyytia & Sinclair, 1993). Yet, no
research has been conducted on humans on the effects of buprenorphine medication and
alcohol consumption nor on buprenorphine and naloxone medication combined.
Buprenorphine has been found to carry a little risk of liver toxicity and research data
indicated that brief intervention strategies may help reduce alcohol intake, but the
existing evidence is still limited. In addition, the effects of buprenorphine in combination
with naloxone and the effect the medication has on alcohol medication is also limited.
Past research has been conducted on rats or presented in the form of literature review.
The purpose of the study is to gain a better understanding of opioid dependency
and its relationship with alcohol in terms of exploring the effect that opioid dependency
medications have on the amount of alcohol patients. The hypothesis that patients who use
buprenorphine/naloxone will consume less alcohol than patients who use buprenorphine
alone was not supported in this study. The results of this study found that people who
took buprenorphine reported fewer drinks than people who took buprenorphine/naloxone.
Although when adjusting for pre-treatment drinking the effect goes away.
There are many limitations of the present study, such as sample size; we
originally aimed to gather 111 participants or more but due to COVID-19, our data
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collection was paused. In addition, the measures rely heavily on self-report measures and
is thus, subject to respondents’ biases. Voluntary participants and convenience sampling
pose the constraint that individuals who consume alcohol more heavily might not like to
respond or participate in the study.
In conclusion, this study provides novel data about opioid use medication
treatment and the effect it has on alcohol consumption in terms of the differences in
effect that buprenorphine and buprenorphine/naloxone may have on human compared to
rats in alcohol consumptions. Although, it should be interpreted with caution owing to the
small sample size and the fact that individuals with opioid use disorder from multiple
clinics were not represented in the sample.
A number of considerations must be addressed in order to improve this area of
research. Future research should be conducted on individuals with a history of alcohol
and opioid use and the effect opioid treatment has on their alcohol consumption. In
addition, prospective studies should consider the effect of different doses of opioid use
treatment medication and the effect it has on alcohol consumption.
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Appendix A
Table 1.
Means and Standard Deviations for Demographic, Covariate, and Outcome Measures
Medication
Buprenorphine
Buprenorphine/Naloxone
M
SD
M
SD
Beck’s Depression Scale 9.26
7.54
2.17
8.07
Beck’s Anxiety Scale

8.00

10.88

8.19

8.67

Perceived Social Support
Scale

5.24

1.73

5.12

1.57

Pretreatment Daily
Drinking

1.20

.50

1.17

.71

Pretreatment Binge
Drinking

1.16

.63

1.43

.95

Current Daily Drinking

1.92

.13

1.18

.11

Current Binge Drinking

1.15

.17

1.43

.14

Note: Beck’s Depression Inventory is scored on a 0 to 63 scale. Beck’s Anxiety Inventory
is scored on a 0 to 63 scale. Multidimensional Scale of Perceived Social Support is
scored on a 1 to 7 scale. Pretreatment daily drinking is the covariate in this study and is
scored on a 0 (Never) to 6 (10 or more) scale. Current daily drinking is scored on a 0
(Never) to 6 (10 or more) scale. Current binge drinking is scored on a 0 (Never) to 5
(Daily or Almost Daily) scale. Scores within the same row with an asterisk are
statistically different at p = .05 or less, two-tailed.

Appendix B
Questionnaire Survey
Age: ________
Gender:

Female

Male

Race/Ethnicity:
American Indian/Alaska Native
Native Hawaiian or other Pacific Islander
White
Black or African American
Hispanic:
Yes
No
Marital Status. Check all that apply.
Never Married
Married
Committed relationship
Widowed
Separated
Divorced
Please indicate your highest level of education you have completed:
____ Grade
High School (12)
Associates degree(14)
Bachelor’s degree
(16)
Master’s degree (18)
Doctoral degree (20)
What is your current employment status?
Full time (40hrs/week)
Part-time (20hrs/week)
Full time student
Part time student
Not employed
Do you have any children? If so, how many?
Yes:______
No
In general, would you say your health is:
Excellent
Very good
Good

Fair
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Poor

Have you ever been diagnosed with ADHD and been prescribed medication for it?
Yes
No
Have you personally been prescribed pain medication?

Yes

No

How long have you been in treatment with Foundation Medical Group? _______
What medication are you currently being prescribed? Check all that apply.
Buprenorphine
(Subutex)

Buprenorphine/Naloxone

Buprenorphine/Hydrochloride

Other: ____________
What is the dose of your prescribed medication? ___________
How long have you been taking this medication? _________
Do you currently take the medication:
Daily as directed Twice a day as directed
directed
Inconsistently

More than directed

Less than

In the past month, what substances have you used? Check all that apply.
Amphetamine Barbiturates Cannabinoids Cocaine Ecstasy
Methamphetamine
Oxycodone
Phencyclidine
Benzodiazepines
Fentanyl
Before starting treatment, what substances were used? Check all that apply.
Amphetamine Barbiturates Cannabinoids Cocaine Ecstasy
Methamphetamine
Oxycodone
Phencyclidine
Benzodiazepines
Fentanyl
Currently, how often do you have a drink containing alcohol?
Never
Monthly or less 2-4 times a month 2-3 times a week
times a week

4 or more

Currently, how many standard drinks containing alcohol do you have on a typical
day?
None
1 or 2
3 or 4
5 or 6
7 or 9
10 or more
Currently, how often do you have six or more drinks on one occasion?
Never
Less than monthly
Monthly
Weekly
Daily or almost daily
Currently, how frequently do you smoke tobacco?
Daily
Less than daily
Not at all
Don’t know
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Before starting treatment, how often did you have a drink containing alcohol?
Never
Monthly or less 2-4 times a month 2-3 times a week
4 or more
times a week
Before starting treatment, how many standard drinks containing alcohol did you
have on a typical day?
None
1 or 2
3 or 4
5 or 6
7 or 9
10 or more
Before starting treatment, how often did you have six or more drinks on one
occasion?
Never
Less than monthly
Monthly
Weekly
Daily or almost daily
Before starting treatment, how frequently did you smoke tobacco?
Daily
Less than daily
Not at all
Don’t know
Before starting treatment, how depressed did you feel?
Not depressed Somewhat depressed Depressed Very depressed
depressed
Before starting treatment, how anxious did you feel?
Not anxious Somewhat anxious Anxious Very anxious
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Extremely

Extremely anxious

Appendix B: Continued
We are interested in how you feel about the following statements. Read each
statement carefully. Indicate how you feel about each statement.
1 = Very strongly disagree
2 = Strongly disagree
3 = Mildly disagree
4 = Neutral
5 = Mildly agree
6 = Strongly agree
7 = Very strongly
1.There is a special person who is around when I am in
need.
2.There is a special person with whom I can share my
joys and sorrows.
3.My family really tries to help me.
4.I get the emotional help and support I need from my
family.
5.I have a special person who is a real source of comfort
to me.
6.My friends really try to help me.
7.I can count on my friends when things go wrong.
8.I can talk about my problems with my family.
9.I have friends with whom I can share my joys and
sorrows.
10. There is a special person in my life who cares about
my feelings.
11.My family is willing to help me make decisions.
12.I can talk about my problems with my friends
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1

2

3

4

5

6

7

1

2

3

4

5

6

7

1
1

2
2

3
3

4
4

5
5

6
6

7
7

1

2

3

4

5

6

7

1
1
1
1

2
2
2
2

3
3
3
3

4
4
4
4

5
5
5
5

6
6
6
6

7
7
7
7

1

2

3

4

5

6

7

1
1

2
2

3
3

4
4

5
5

6
6

7
7

Appendix B: Continued
Beck’s Depression Inventory
1. Sadness
0.
1.
2.
3.

I do not feel sad.
I feel sad much of the time
I am sad all the time.
I am so sad or unhappy that I can’t stand it.

2. Pessimism
0.
1.
2.
3.

I am not discouraged about my future.
I feel more discouraged about my future than I used to.
I do not expect things to work out for me.
I feel my future is hopeless and will only get worse.

3. Past Failure
0. I do not feel like a failure.
1. I have failed more than I should have.
2. As I look back, I see a lot of failures.
3. I feel I am a total failure as a person.
4. Loss of Pleasure
0.
1.
2.
3.

I get as much pleasure as I ever did from the things I enjoy.
I don’t enjoy things as much as I used to.
I get very little pleasure from the things I used to enjoy.
I can’t get any pleasure from the things I used to enjoy.

5. Guilty feelings
1. I don’t feel particularly guilty.
2. I feel guilty over many things I have done or should have done.
3. I feel quite guilty most of the time.
4. I feel guilty all the time.
6. Punishment feelings
1. I don’t feel I am being punished.
2. I feel I may be punished.
3. I expect to be punished.
4. I feel I am being punished.
7. Self-Dislike
1. I feel the same about myself as ever.
2. I have lost confidence in myself.
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3. I am disappointed in myself.
4. I dislike myself.
8. Self-Criticalness
1. I don’t criticize or blame myself more than usual.
2. I am more critical of myself than I used to be.
3. I criticize myself for all of my faults.
4. I blame myself for everything bad that happens.
9. Suicidal Thoughts or Wishes
1. I don’t have any thoughts of killing myself.
2. I have thoughts of killing myself, but I wouldn’t carry them out.
3. I would like to kill myself.
4. I would kill myself if I had the chance.
10. Crying
1. I don’t cry any more than I used to.
2. I cry more than I used to.
3. I cry over every little thing.
4. I feel like crying, but I can’t’.
11. Agitation
1. I am no more restless or would up than usual.
2. I feel more restless or would up than usual.
3. I am so restless or agitated, it’s hard to stay still.
4. I am so restless or agitated that I have to keep moving or doing
something.
12. Loss of Interest
1. I have not lost interest in other people or activities.
2. I am less interested in other people or things than before.
3. I have lost most of my interest in other people or things.
4. It’s hard to get interested in anything.
13. Indecisiveness
1. I make decisions about as well as ever.
2. I find it more difficult to make decisions than usual.
3. I have much greater difficulty in making decisions than I used to.
4. I have trouble making any decisions.
14. Worthlessness
1. I do not feel I am worthless.
2. I don’t consider myself as worthwhile and useful as I used to.
3. I feel more worthless as compared to others.
4. I feel utterly worthless.
15. Loss of energy
1. I have as much energy as ever.
2. I have less energy than I used to have.
3. I don’t have enough energy to do very much.
4. I don’t have enough energy to do anything.
16. Changes in sleeping patterns
1. I have not experienced any change in my sleeping.
2. I sleep somewhat more than usual.
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3. I sleep somewhat less than usual.
4. I sleep a lot more than usual.
5. I sleep a lot less than usual.
6. I sleep most of the day.
7. I wake up 1-2 hours early and can’t get back to sleep.
17. Irritability
1. I am not more irritable than usual.
2. I am more irritable than usual.
3. I am much more irritable than usual.
4. I am irritable all the time.
18. Changes in Appetite
1. I have not experienced any change in my appetite.
2. My appetite is somewhat less than usual.
3. My appetite is somewhat greater than usual.
4. My appetite is much less than before.
5. My appetite is much greater than usual.
6. I have no appetite at all
7. I crave food all the time.
19. Concentration Difficulty
1. I can concentrate as well as ever.
2. I can’t concentrate as well as usual.
3. It’s hard to keep my mind on anything for very long.
4. I find I can’t concentrate on anything.
20. Tiredness or Fatigue
1. I am no more tired or fatigued than usual.
2. I get more tired or fatigues more easily than usual.
3. I am too tired or fatigues to do a lot of the things I used to do.
4. I am too tired or fatigues to do most of the things I used to do.
21. Loss of Interest in Sex
1. I have mot noticed any recent change in my interest in sex
2. I am less interested in sex than I used to be.
3. I am much less interested in sex now.
4. I have most interest in sex completely.
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Appendix B: Continued
Please carefully read each item in the list. Indicate how much you have been
bothered by that symptom during the past month, including today, by circling the
number in the corresponding space in the column next to each symptom.

Not At All

Mildly but it didn’t
bother me much.

Numbness or tingling

Moderately - it wasn’t pleasant
at times
Severely – it bothered
me a lot

2
0

1

3

0

1

0

1

Unable to relax

0

1

2

3

Fear of worst
happening

0

1

2

3

Dizzy or lightheaded

0

1

2

3

Heart
pounding/racing

0

1

2

3

0

1

0

1

0

1

Feeling hot

2
3

Wobbliness in legs

2
3

Unsteady

2
3

Terrified or afraid

2
3

Nervous

2
3
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Feeling of choking

2
0

1

3

Hands trembling

0

1

2

3

Shaky / unsteady

0

1

2

3

0

1

0

1

Fear of losing control
Difficulty in
breathing

2
3
2
3

Fear of dying

2
0

1

3

Scared

2
0

1

3

Indigestion

2
0

1

3

Faint / lightheaded

0

1

2

3

Face flushed

0

1

2

3

Hot/cold sweats

0

1

2

3
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